Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 1997

View Archived Issues

MGI Pharma: Q3 1997 highlights

Bone Care: Q3 1997 highlights

Lilly: Q3 1997 highlights

BioCryst: Q3 1997 highlights

Atlantic's 2-5A improves efficacy of antisense compounds

First report of efficacy for rotavirus vaccine in a developing country

ADCON-L up for advisory committee review

Dusa reports positive phase III results for Levulan PDT

Hyal invests in breast cancer detection technology

Major advance in thalassemia research reported

Alza acquires rights to Ditropan

TBC-1269 enters phase II for treatment and prevention of asthma

Nicotrol launched in Austria as OTC

VEGF inhibitors described by Zeneca

Janssen discloses agents that promote gastrointestinal motility

New antidiabetic agents from Boehringer Mannheim

Abbott develops inhibitors of LT biosynthesis

Improved DNA topoisomerase poisons discovered at Rutgers

Anti-H. pylori cephems claimed by Fujisawa

New antimitotic agents presented by Kyowa Hakko

New DC-107 derivative presented at cancer meeting

Cellular target of new antitumor agent from Nippon Shinyaku identified

Nikken presents new modulator of multidrug resistance

NCA-0465: new antitumor indoloquinoxaline derivative

Preclinical studies on TZT-1027, an antitumor dolastatin 10 derivative

Taiho reports preclinical studies on TAS-103

Potent, topically active glucocorticoid from RPR shows potential for bronchial asthma

Development of antipsychotic agent discontinued

Synthetic retinoid with antiangiogenic/apoptosis-inducing effects from Taiho

MS-209 reverses MDR mediated by MRP and P-glycoprotein

Jenner Technologies changes name

Photofrin now available in France and Germany

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...